These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35814507)

  • 1. Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study.
    Kaushal K; Agarwal S; Sharma S; Goswami P; Singh N; Sachdev V; Poudel S; Das P; Yadav R; Kumar D; Pandey G; Gunjan D; Saraya A
    J Clin Exp Hepatol; 2022; 12(4):1102-1113. PubMed ID: 35814507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in the intestinal microenvironment during development of alcoholic fatty liver disease and related effects of probiotic therapy].
    Zhang B; Lu XL; Song YH; Shi HT; Li J; Geng Y
    Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):848-52. PubMed ID: 23206305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling.
    Sowa JP; Atmaca Ö; Kahraman A; Schlattjan M; Lindner M; Sydor S; Scherbaum N; Lackner K; Gerken G; Heider D; Arteel GE; Erim Y; Canbay A
    PLoS One; 2014; 9(7):e101444. PubMed ID: 24988316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
    Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
    Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
    Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
    J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Intestinal Permeability and Decreased Resiliency of the Intestinal Barrier in Alcoholic Liver Disease.
    Swanson GR; Garg K; Shaikh M; Keshavarzian A
    Clin Transl Gastroenterol; 2024 Apr; 15(4):e00689. PubMed ID: 38334953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.
    Shen SH; Zhong TY; Peng C; Fang J; Lv B
    BMC Complement Med Ther; 2020 Feb; 20(1):34. PubMed ID: 32024509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
    Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
    Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duodenal CD8+ T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol-associated liver disease in humans.
    Maccioni L; Loriot A; Dewulf J; Bommer G; Horsmans Y; Lanthier N; Leclercq I; Schnabl B; Stärkel P
    Aliment Pharmacol Ther; 2022 Sep; 56(6):1055-1070. PubMed ID: 35919965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
    Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
    Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease.
    Xin D; Zong-Shun L; Bang-Mao W; Lu Z
    Hepatogastroenterology; 2014; 61(129):136-40. PubMed ID: 24895809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lacticaseibacillus rhamnosus LRa05 alleviated liver injury in mice with alcoholic fatty liver disease by improving intestinal permeability and balancing gut microbiota.
    Gu J; Chen Y; Wang J; Gao Y; Gai Z; Zhao Y; Xu F
    Benef Microbes; 2024 Jul; ():1-13. PubMed ID: 38960385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the gut barrier for the treatment of alcoholic liver disease.
    Zhou Z; Zhong W
    Liver Res; 2017 Dec; 1(4):197-207. PubMed ID: 30034913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease.
    Trépo E; Ouziel R; Pradat P; Momozawa Y; Quertinmont E; Gervy C; Gustot T; Degré D; Vercruysse V; Deltenre P; Verset L; Gulbis B; Franchimont D; Devière J; Lemmers A; Moreno C
    J Hepatol; 2013 Aug; 59(2):344-50. PubMed ID: 23557869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
    PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication.
    Israelsen M; Kim M; Suvitaival T; Madsen BS; Hansen CD; Torp N; Trost K; Thiele M; Hansen T; Legido-Quigley C; Krag A;
    JHEP Rep; 2021 Oct; 3(5):100325. PubMed ID: 34401690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction.
    Guo C; Li Q; Chen R; Fan W; Zhang X; Zhang Y; Guo L; Wang X; Qu X; Dong H
    Food Funct; 2023 Feb; 14(4):2138-2148. PubMed ID: 36752061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the
    Wang Y; Wang Z; Wan Y; Jin F; Shi X; Xing Z; Tian B; Li B
    Front Nutr; 2023; 10():1147423. PubMed ID: 37020807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.